07th week of 2015 patent applcation highlights part 51 |
Patent application number | Title | Published |
20150045285 | BIOFILM INHIBITOR - The biofilm inhibitor of the present invention contains a lectin, at least one recognizable sugar chain of which is N-acetylglucosamine (G/LcNAc). | 2015-02-12 |
20150045286 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS - Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided. | 2015-02-12 |
20150045287 | ANTIMICROBIAL COMPOSITION FOR INHIBITING MICROBIAL ORGANISMS AND THE METHOD THEREOF - The invention relates to a method of controlling or combating microbial organism by applying an antimicrobial peptide to the microbial organisms, wherein said antimicrobial peptide derived from | 2015-02-12 |
20150045288 | COMPOSITION - The present invention relates to anti-contaminant composition comprising a cell-free fermentation product of one or more | 2015-02-12 |
20150045289 | METHOD OF PRE-PREPARING MEDICATIONS FOR THERAPEUTIC USES - The present invention relates to the method of pre-preparing pharmaceutical compositions for therapeutic uses, particularly pre-preparing medications for treating patients (e.g., cancer patients and the like) by intravenous infusion. | 2015-02-12 |
20150045290 | Bacillus Sp. Biosurfactants, Composition Including Same, Method for Obtaining Same, and Use Thereof - Biosurfactants produced by a strain of | 2015-02-12 |
20150045291 | LIPOPEPTIDE CONJUGATES COMPRISING SPHINGOLIPID AND HIV GP41 DERIVED PEPTIDES - The invention provides conjugates comprising a short isolated peptide coupled to a sphingolipid, the peptide comprising a sequence derived from the HIV-1 gp41. The sphingolipid-peptide conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV. | 2015-02-12 |
20150045292 | METHODS AND COMPOSITION FOR INDUCING SATIETY - A flowable or spoonable medicament, food, food ingredient or food supplement is useful for inducing satiety. It comprises a protein and a methylcellulose (MC), wherein the weight ratio w(protein)/w(MC) is at least 0.7/1.0 and the methylcellulose has anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.36 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups. | 2015-02-12 |
20150045293 | MELANOCORTIN ANALOGS HAVING ENHANCED ACTIVITY AND TRANSPORT - Described herein are melanocortin analogs having enhanced activity and transport. | 2015-02-12 |
20150045294 | ENERGY-RICH LIQUID NUTRITIONAL COMPOSITION HAVING IMPROVED ORGANOLEPTIC PROPERTIES - The object of the present invention is to provide a liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, comprising a high protein content, in particular micellar casein as major protein source, in a small volume of liquid, in particular 6 to 20 g protein per 100 ml of the liquid composition, the composition further comprising lactic acid and having a pH in the range of 6 to 8. It is also an object of the invention to provide an improved manufacturing process for such liquid enteral compositions. | 2015-02-12 |
20150045295 | DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY - A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable. | 2015-02-12 |
20150045296 | METHOD FOR TREATING DIABETIC RETINOPATHY - Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided. | 2015-02-12 |
20150045297 | GROWTH DIFFERENTIATION FACTOR (GDF) FOR TREATMENT OF DIASTOLIC HEART FAILURE - The technology described herein relates to treatments for, e.g., diastolic heart failure, cardiac hypertrophy, and related conditions. | 2015-02-12 |
20150045298 | COMPOSITION INCLUDING STEM CELL-DERIVED MICROVESICLES FOR PROMOTING NEUROGENESIS - The present invention relates to a composition including stem cell-derived microvesicles as an active ingredient for promoting neurogenesis. The stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of nerves and also promote angiogenesis in vascular endothelial cells, and thus can be usefully used in treatment of neurological damage. | 2015-02-12 |
20150045299 | TGFB TYPE II-TYPE III RECEPTOR FUSIONS - Certain embodiments are directed to novel heterotrimeric fusions in which the ectodomain of the TGF-β type II receptor (TβP?II) is coupled to the N- and C-terminal ends of the endoglin-domain of the TGF-β type III receptor (TpRIIIE). Certain embodiments are directed to novel heterotrimeric polypeptides in which the ectodomain of the TGF-β type II receptor (TI3RII) is coupled to the N- and C-terminal ends of the endoglin-domain (E domain) of the TGF-β type III receptor (TI3RIII). This trimeric receptor, known as RER, can bind all three TGF-β isoforms with sub-nanomolar affinity and is effective at neutralizing signaling induced by all three TGF-β isoforms, but not other ligands of the TGF-β superfamily, such as activins, growth and differentiation factors (GDFs), and bone morphonogenetic proteins (BMPs). | 2015-02-12 |
20150045300 | FAST DISSOLVING PHARMACEUTICAL COMPOSITION - The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises both the polysaccharides levan and inulin. | 2015-02-12 |
20150045301 | METHODS AND USES OF ANP (ATRIAL NATRIURETIC PEPTIDE), BNP (BRAIN NATRIURETIC PEPTIDE) AND CNP (C-TYPE NATRIURETIC PEPTIDE)-RELATED PEPTIDES AND DERIVATIVES THEREOF FOR TREATMENT OF RETINAL DISORDERS AND DISEASES - The invention provides NP compounds such as proteins, peptides, peptidomimetics, derivatives and analogs for treating retinal disorders and diseases. | 2015-02-12 |
20150045302 | PEPTIDES - A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin. | 2015-02-12 |
20150045303 | Pharmaceutical Composition Suitable for Treatment of Haemophilia - The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia. | 2015-02-12 |
20150045304 | BONE SUBSTITUTE NANOCOMPOSITES AND METHODS OF SYNTHESIS USINGMULTIPHOSPHORYLATED PEPTIDES - The invention relates to peptides including DEDE(SSD) | 2015-02-12 |
20150045305 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS - Described herein is a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising administration of an effective amount of one or more of a potassium channel blocker and an effective amount of one or more of a late sodium channel blocker. Also provided are methods for modulating ventricular and atrial rhythm and rate. Also provided are pharmaceutical formulations that are suitable for such combined administration. | 2015-02-12 |
20150045306 | DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE - This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate. | 2015-02-12 |
20150045307 | IDENTIFICATION OF A NOVEL BHD GENE - The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating BHD skin lesions. | 2015-02-12 |
20150045308 | Compositions and Methods of Treating Cancer - The present invention provides compositions and methods of treating various disorders associated with aberrant cell growth. | 2015-02-12 |
20150045309 | CYCLOSPORIN EMULSIONS - Disclosed herein is a composition comprising cyclosporin A at a concentration between about 0.001% (w/v) and about 1.0% (w/v), a plant oil at a concentration between about 0.01% (w/v) and about 10% (w/v), and macrogol 15 hydroxystearate at a concentration between about 0.01% (w/v) and about 10% (w/v). | 2015-02-12 |
20150045310 | NOVEL ENGINEERED POTENT CYTOTOXIC STAPLED BH3 PEPTIDES - Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided. | 2015-02-12 |
20150045311 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME - The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride. | 2015-02-12 |
20150045312 | Use of Compounds Elevating Glutathione Levels for the Treatment of Autism, Autistic Spectrum Disorders and Fragile X Syndrome - Methods of treating autism, autistic spectrum disorders or Fragile X syndrome comprised of administering molecules that engage the cystine-glutamate exchange (System x | 2015-02-12 |
20150045313 | Ectoparasiticidal Methods and Formulations - Provided are novel methods and formulations for topically controlling ectoparasite infestations in animals using spinetoram or a pharmaceutically acceptable salt thereof. | 2015-02-12 |
20150045314 | PESTICIDAL COMPOSITION - Non-aqueous pesticidal macrolide compositions are provided which comprise (A) a major amount of at least one non-aqueous solvent selected from a glycol ether and a lactimide; (B) a minor amount of a mixture of (i) at least one pesticide selected from abamectin and emamectin benzoate, and (ii) optionally, at least one surfactant. In one embodiment, the at least one pesticide selected from abamectin and emamectin benzoate is present in the composition in an amount of at least 7% by weight. In another embodiment, the compositions of the invention are chemically stable. The compositions of the invention can be used directly as a concentrate for treating or reducing tree pest infestations by trunk injection or with dilution in water for control of pests in crops of useful plants. | 2015-02-12 |
20150045315 | METHOD OF TREATING HYPERESTHESIA, PARESTHESIA, DOLOR, AND PRURITUS CAUSED BY INSECT STINGS OR NOXIOUS WEEDS OR PLANTS USING AVERMECTIN COMPOUND - A method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by an insect or arthropod sting or bite, or a skin contact with a noxious weed or plant is disclosed. The method includes topically applying a dermatological composition containing an avermectin compound to an affected area immediately after said sting or bite, or said skin contact occurs. The method further includes moistening the affected area first prior to application of the dermatological composition. | 2015-02-12 |
20150045316 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 - The invention provides semisynthetic derivatives of Nystatin A | 2015-02-12 |
20150045317 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 2015-02-12 |
20150045318 | COMPONENT AND METHOD FOR TREATING VIRAL DISEASE - A method for treating viral infection includes administering to a subject in need thereof a composition containing P2X receptor antagonists. The methods may achieve preventive or therapeutic effect on hand foot and mouth disease by inhibiting viruses. The P2X receptor antagonists can inhibit infection by a positive-sense single-stranded RNA picornavirus. The virus may be an enterovirus or a Coxsackie virus, such as human enterovirus 71. The P2X receptor antagonist may be PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNP-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, or a pharmaceutically acceptable salt thereof. | 2015-02-12 |
20150045319 | URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS - This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P | 2015-02-12 |
20150045320 | METHODS AND COMPOSITION FOR INDUCING SATIETY - A flowable or spoonable medicament, food, food ingredient or food supplement is useful for inducing satiety. It comprises (a) one or more mono-, di- and/or oligosaccharides and (b) a methylcellulose, wherein the methylcellulose has anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is from 0.17 to 0.36, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups. | 2015-02-12 |
20150045321 | HYALURONIC ACID BASED FORMULATIONS - Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on low molecular weight hyaluronic acids and pharmaceutically acceptable salts thereof, and methods of manufacturing same. | 2015-02-12 |
20150045322 | COMBINATION TREATMENT COMPRISING SULPHATED GLYCOSAMINOGLYCANS FOR INDUCING LABOR - The present invention refers to the use of certain sulfated glycosaminoglycans for inducing labor. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are used in a combination therapy together with treatment capable of promoting cervical ripening or capable of promoting myometrial contractions of the uterus. | 2015-02-12 |
20150045323 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR - Disclosed are compounds having the formula: | 2015-02-12 |
20150045324 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY - The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient. | 2015-02-12 |
20150045325 | FUSED AROMATIC PTP-1B INHIBITORS - The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes. | 2015-02-12 |
20150045326 | NOVEL PYRAZINE AMIDE COMPOUNDS - The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, | 2015-02-12 |
20150045327 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS - The present invention discloses compounds according to Formula I: | 2015-02-12 |
20150045328 | DISUBSTITUTED ARYL OXY DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to aryl oxy derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2015-02-12 |
20150045329 | SUBSTITUTED TETRACYCLINE COMPOUNDS - The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression. | 2015-02-12 |
20150045330 | PROPHYLACTIC AND THERAPEUTIC DRUG FOR AMYOTROPHIC LATERAL SCLEROSIS AND METHOD OF SCREENING THEREFOR - The present invention provides a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis, which contains an anacardic acid derivative, and a method of screening for a prophylactic and/or therapeutic drug for amyotrophic lateral sclerosis, utilizing an induced pluripotent stem cell derived from a patient with amyotrophic lateral sclerosis. | 2015-02-12 |
20150045331 | Collagen Stimulators and Their Use in the Treatment of Skin - Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ cosmetic composition comprising novel active agents that enhance collagen production in the skin. | 2015-02-12 |
20150045332 | Novel Sphingosine 1-Phosphate Receptor Antagonists - The present invention relates to sphingosine-1-phosphate (S1P) receptors and compounds of the general formula: | 2015-02-12 |
20150045333 | LIQUID COMPOSITIONS COMPRISING VITAMIN D AND USES THEREOF - The present invention relates to a liquid composition comprising vitamin D, or a salt thereof. Specific embodiments employ 5000 IU to 250,000 IU, and include sorbate and benzoate as a preserving agent. | 2015-02-12 |
20150045334 | DIAGNOSTIC METHODS OF EOSINOPHILIC ESOPHAGITIS - Embodiments of the invention are directed to methods of diagnosing eosinophilic esophagitis (EoE), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EoE, analyzing to obtain relatedness information relative to an EoE cohort and making a determination as to the EoE status of the subject, wherein an analysis indicating grouping with an EoE cohort or a quantitative score similar to that of an EoE cohort are indicative of EoE in the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EoE in a subject. | 2015-02-12 |
20150045335 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITONS AND METHODS - According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy. | 2015-02-12 |
20150045336 | TAZOBACTAM AND CEFTOLOZANE ANTIBIOTIC COMPOSITIONS - This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of making those compositions, and related methods and uses of these compositions. | 2015-02-12 |
20150045337 | CONTROLLED RELEASE COMPOSITIONS AND THEIR METHODS OF USE - The present invention relates to a composition, the composition including a therapeutically effective amount of at least one active agent, and a base including, an amount of colloidal silica; at least one oil; and at least one surfactant, wherein the viscosity of the composition is below 1000 mPas at a shear rate of 100 l/s and at a temperature of 20° C. | 2015-02-12 |
20150045338 | METHODS FOR TREATING INTRAPULMONARY INFECTIONS - This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane. | 2015-02-12 |
20150045339 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF - The object is to provide an Fms-like tyrosine kinase 3 (FLT3) inhibitor useful as a therapeutic agent for acute myeloid leukemia (AML). A novel nitrogen-containing heterocyclic compound represented by the general formula [1] or a salt thereof is provided. The compound or a salt thereof of the present invention can be used as an active ingredient of a pharmaceutical composition for a treatment of a disease or condition relating to FLT3, such as acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). | 2015-02-12 |
20150045340 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS - The present invention relates to novel β-lactam compounds, their preparation and use. In particular, this invention relates to novel β-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation. | 2015-02-12 |
20150045341 | DISUBSTITUTED ARYL AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to disubstituted aryl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2015-02-12 |
20150045342 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF - A novel compound which has an excellent aurora A-selective inhibitory action and is useful as an orally administrable anticancer agent is provided. Also, a novel agent for potentiation of anti-tumor effect of microtubule agonists, which include a taxane anticancer agent, and a combination therapy are provided. A piperidine compound represented by a general formula (I) or a salt thereof:
| 2015-02-12 |
20150045343 | KINASE INHIBITORS - Methods of inhibiting kinases using kinase inhibitors having olefin moieties are disclosed. | 2015-02-12 |
20150045344 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF - The present invention relates to novel 4-(4-cyano-2-thioaryl)dihydropyrimidin-2-one derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system. | 2015-02-12 |
20150045345 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)ETHOXY)PROPYL)AZETIDIN-3-OL OR SALT THEREOF - This solid pharmaceutical composition is useful as a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol, which is excellently elutable and moldable and is stable in long-term storage, or a salt thereof. | 2015-02-12 |
20150045346 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 2015-02-12 |
20150045347 | TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS - Compounds having the following formula: (I) wherein: A is an optionally substituted triazole, or a stereoisomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation. | 2015-02-12 |
20150045348 | PDE9 inhibitors with imidazo triazinone backbone - This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). | 2015-02-12 |
20150045349 | HETEROCYCLIC COMPOUND - The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. | 2015-02-12 |
20150045350 | METHOD FOR NORIBOGAINE TREATMENT IN PATIENTS ON METHADONE - A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment. | 2015-02-12 |
20150045351 | TRICYCLIC COMPOUND - The present invention provides a compound having a superior serotonin 5-HT | 2015-02-12 |
20150045352 | COMPOSITIONS CONTROLLING pH RANGE OF RELEASE AND/OR RELEASE RATE - The present invention provides a composition controlling a pH range of release and/or a release rate, which contains (i) a thienotriazolodiazepine compound of the formula (I) | 2015-02-12 |
20150045353 | FORMULATIONS CONTAINING GAMMA SECRETASE MODULATORS, METHODS FOR PREPARATION AND DELIVERY THEREOF - In accordance with the present invention, there are provided formulations of gamma secretase modulators (GSMs) which are suitable for oral delivery and have improved transport properties relative to prior art formulations thereof. Also provided are methods for the preparation of such improved formulations and uses thereof for the delivery of GSMs to subjects in need thereof. | 2015-02-12 |
20150045354 | Anti-Malarial Agents - The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R | 2015-02-12 |
20150045355 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS - Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor. | 2015-02-12 |
20150045356 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS - Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof. | 2015-02-12 |
20150045357 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF - This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a [(1-Piperazinyl)-4-pyridinylmethyl]-Naphtho[1,2-b]furan structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases. | 2015-02-12 |
20150045358 | PHARMACEUTICAL COMPOSITION FOR TREATING DISORDERS ASSOCIATED WITH INSULIN RESISTANCE - A pharmaceutical composition for treating disorders associated with insulin resistance is disclosed, and the composition comprises at least one inhibitor which is an effective agent to suppress endothelin-1-stimulated resistin gene expression through decreasing the endothelin-1-stimulated phosphorylation of proteins downstream of endothelin type A receptor, wherein the downstream signaling molecules comprise ERK1/2, JNKs, AKT, and STAT3 proteins, and wherein the inhibitor is selected from at least one antagonist of the endothelin type A receptor or downstream signaling proteins. | 2015-02-12 |
20150045359 | MORPHOLINE COMPOUNDS AND USES THEREOF - The present invention relates to compounds of formula | 2015-02-12 |
20150045360 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 2015-02-12 |
20150045361 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2015-02-12 |
20150045362 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 - The invention provides compounds of the formula (I): | 2015-02-12 |
20150045363 | Hedgehog Pathway Inhibition for Cartilage Tumor and Metachondromatosis Treatment - Hedgehog pathway inhibitors, such as small molecules, are used to prevent, slow, block the formation of cartilage tumors as well as exostosis or enchondromas. | 2015-02-12 |
20150045364 | Pyridine and Pyrazine derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 2015-02-12 |
20150045365 | Novel Anti-Cancer Agents - The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. | 2015-02-12 |
20150045366 | SPRAY DRIED FORMULATIONS - The invention provides a spray dried formulation of Compound I: or a salt thereof as well as compositions comprising the spray dried formulations, and methods for making and using the spray dried formulations. | 2015-02-12 |
20150045367 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 - Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity. | 2015-02-12 |
20150045368 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF - Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein. | 2015-02-12 |
20150045369 | NOVEL MARKERS FOR DETECTING MICROSATELLITE INSTABILITY IN CANCER AND DETERMINING SYNTHETIC LETHALITY WITH INHIBITION OF THE DNA BASE EXCISION REPAIR PATHWAY - Described are mismatch repair (MMR-)deficient tumors. Markers are presented herein having a high sensitivity to detect whether a tumor is mismatch repair deficient or not. The markers are particularly mutations in microsatellite regions. Accordingly, methods and materials are provided for diagnosing microsatellite instability of a tumor. Such a method comprises determining the presence of these markers. Further, kits are provided to detect the presence of these markers (or subsets thereof) in a sample. | 2015-02-12 |
20150045370 | SIK INHIBITOR FOR USE IN A METHOD OF TREATING AN INFLAMMATORY AND/OR IMMUNE DISORDER - The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders. | 2015-02-12 |
20150045371 | Salts of a dihydroquinazoline derivative - The invention relates to besylate and tosylate salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treating and/or preventing virus infections, and to the use thereof to produce drugs for use in treating and/or preventing diseases, in particular use as antiviral agents, in particular against cytomegaloviruses. | 2015-02-12 |
20150045372 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR - The present invention relates to processes for preparing pyrazole derivatives of Formula (I) and salts and pharmaceutical compositions of the salts thereof, useful as modulators of 5-HT | 2015-02-12 |
20150045373 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE - This invention provides compounds having the structure | 2015-02-12 |
20150045374 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS - The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein. | 2015-02-12 |
20150045375 | NOVEL COMPOUNDS - Pyrimidone compounds of formula (I): | 2015-02-12 |
20150045376 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA - Piperidino-dihydrothienopyrimidine sulfoxides of formula I | 2015-02-12 |
20150045377 | PHARMACEUTICAL COMPOUNDS - The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of the serine/threonine kinase, AKT. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer. | 2015-02-12 |
20150045378 | AROMATIC RING COMPOUND - Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): | 2015-02-12 |
20150045379 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2015-02-12 |
20150045380 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF - The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6. | 2015-02-12 |
20150045381 | COMPOSITIONS AND METHODS FOR SUSTAINED ENERGY AND ENHANCED WEIGHT LOSS - Disclosed are compositions and methods for sustained energy and enhanced weight loss. A composition for weight loss and sustained energy in a person comprises an effective amount of one or more B vitamins and an effective amount of one or more of lysine, leucine, and methionine. The composition may further comprises an effective amount of one or more of a carbohydrate, cobalmin, and carnitine. The composition may be in a form administrable to a person orally, by intravenous infusion, or by intramuscular injection. A method of losing weight and sustaining energy comprises administering, to a person, a composition comprising an effective amount of one or more B vitamins and an effective amount of one or more of lysine, leucine, and methionine. The method may further comprise administering an effective amount of at least one of a carbohydrate, cobalmin, and carnitine. | 2015-02-12 |
20150045382 | RIFAXIMIN COMPLEXES - There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex. | 2015-02-12 |
20150045383 | TREATING PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT - An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment | 2015-02-12 |
20150045384 | Morphan and Morphinan Analogues, and Methods of Use - The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof. | 2015-02-12 |